Sodium cyclamate and cyclohexylamine

These substances were identified for action under the Chemicals Management Plan (CMP).

• Summary of publications
• Follow-up activities
• Timelines
• Background

Summary of publications

CAS RN	Common name	DSL name	Public comments on the draft screening assessment	Final screening assessment	Conclusion on section 64 criteria	Follow-up activities
139-05-9	Sodium cyclamate	Sulfamic acid, cyclohexyl-, monosodium salt	HTML	HTML	Does not meet	None planned at this time
108-91-8	Cyclohexylamine (CHA)	Cyclohexanamine				Significant New Activity (SNAc) provisions

Follow-up activities

Sodium cyclamate

Although a risk to human health or the environment has not been identified at current levels of exposure, sodium cyclamate has health effects of concern based on its potential to cause reproductive effects. Therefore, there may be a potential risk if exposure to this substance was to increase. An analysis of information related to current and potential future uses of sodium cyclamate suggest that it is unlikely that exposure will increase to levels of concern to human health. For this reason, follow-up activities to track changes in exposure and/or commercial use patterns for sodium cyclamate are not being considered at this time.

Cyclohexylamine

Although cyclohexylamine was not considered to be harmful to human health at levels of exposure considered in the assessment, it is considered to have a health effect of concern due to its potential to cause reproductive effects. Therefore, there may be a concern if exposures were to increase. The proposed follow-up activity for cyclohexylamine is to apply the SNAc provisions of the Canadian Environmental Protection Act, 1999 (CEPA 1999).

Timelines

Date	Activity
April 9, 2022	Publication in the Canada Gazette, Part I: Vol. 156, No. 15 of a notice of intent to amend the Domestic Substances List to apply the SNAc provisions of CEPA 1999 to cyclohexylamine and start of 60-day public comment period.
April 9, 2022	Publication of the final screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 156, No. 15.
December 14, 2019	Publication and start of 60-day public comment period on the draft screening assessment (including follow-up activities). The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 50.

Background

Cyclohexylamine (CAS RN 108-91-8) was identified as being part of the Aliphatic Amines Group at the outset of the third phase of the CMP. This substance was subsequently moved to this assessment of sodium cyclamate, since cyclohexylamine is a metabolite of sodium cyclamate in mammals and cyclohexylamine data were used to assess the risk to human health of both substances.